Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Healthcare, Regulatory and Reimbursement Landscape – JapanThe Decreasing Population in the Working Age Group and the Rising Elderly Population Represents a Challenge for Policy Planners in Japan
By: Rajesh Gunnam The population of Japan is declining due to the: • Higher mortality rate (8.6 in 2005 to 9.1 in 2009 per 1,000 population) than the live birth rate (8.4 in 2005 to 8.5 in 2009 per 1,000 population). • Decrease in the fertility rate (1.6 in 1990 to 1.3 in 2009 per woman). The primary reasons are due to the increased usage of contraceptives (20% in 1995 and 55% in 2000) and the increased adoption of family planning techniques. • Low net rate of immigration. • High cost of living due to high education costs and the high population density of approximately 339 per square km. The population aged 65 years and above is increasing and is projected to reach approximately 35.3 million by 2020. The elderly population of Japan doubled at a faster rate than in the US and European countries due to higher life expectancy, better health care facilities and strong financial support for the elderly population. Japan recorded the highest rank for population aged 100 years and above for the 41st consecutive year in 2011, according to statistics released by the Ministry of Health of Japan. For Sample Pages, please click or add the below link to your browser: http://globaldata.com/ The pharmaceutical market in Japan was worth approximately $77 billion in 2010 and is projected to reach approximately $137 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 5.9%. Japan was the second largest market in the world in terms of drug sales, scientific and medical research, technology and machinery in 2010. The size of the medical device market was approximately $39 billion in 2010. Japan was ranked third behind the US and Germany in 2010 in terms of the size of the medical device market. The market is projected to reach approximately $62 billion by 2020 at a projected CAGR of 4.8%. Ophthalmic devices (15%), in vitro diagnostics (12%) and cardiovascular devices (11%) were the major segments in the medical devices market in 2010. The Japanese government announced an “action program for the faster evaluation of medical devices” under the “basic policies for economic and financial reform,” with an aim of increasing foreign investment in 2009. The primary objectives for the action program included: • Increasing the number of reviewers from 35 to 104. • Classifying medical devices into three levels based on the novelty level, with each level evaluated by a specialized team. • Establishing evaluation standards and guidelines. GlobalData, the industry analysis specialist, has released its report, “Healthcare, Regulatory and Reimbursement Landscape - Japan”. The report is an essential source of information and an analysis on the healthcare, regulatory and reimbursement landscape of Japan. The report identifies the key trends in the healthcare market of Japan. The report also provides insights on the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Japan. Most importantly, the report provides valuable insights on the trends and segmentation of pharmaceutical and medical devices market. This report is built using data and information sourced from proprietary databases, secondary research and inhouse analysis by GlobalData’s team of industry experts. For further details, please click or add the below link to your browser: http://globaldata.com/ Visit our report store: http://www.globaldata.com/ For more details contact: pressreleases@ North America: +1 646 395 5477 Europe: Asia Pacific: # # # GlobalData is a global market intelligence services company providing information research and analysis products and services. End
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number